Deal-making is one of the key strategies employed by pharma companies to fuel growth opportunities. On a spectrum that ranges from intramural organic growth to extramural outright acquisitions, pharma deal-making occupies an intermediate position. One can easily argue that analogous to semi-active investment, this approach should yield highest return for the company as well as its investors on a risk-normalised basis.
Taking an integrated high-throughput approach allows the cross-sectional assessment of the deal-making activities of a group of companies over a certain period of time in an effi cient manner. In line with this framework, one can decompose the pharma deal-activity into various elements that integrates science at the bottom of the pyramid through to corporate strategy at the top of the pyramid. This integrated approached could be construed as an enterprise-wide deal activity scorecard.
Competitive Deal Activity Profiling (CDAP©)